Significant SARS-CoV-2 RNA decay during remdesivir treatment in real life COVID-19 hospitalized patients

European Meeting on HIV & Hepatitis 2021

Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers

European Meeting on HIV & Hepatitis 2021

Long-acting HIV capsid inhibitor effective as PrEP in a SHIV rhesus macaque model

European Meeting on HIV & Hepatitis 2021

Prevalence of genotypic baseline risk factors of cabotegravir+rilpivirine failure among ARV-naïve patients

European Meeting on HIV & Hepatitis 2021

HIV-1 subtypes B, G and CRF02_AG transmission cluster in Migrants population followed in Portugal based on sequence data

European Meeting on HIV & Hepatitis 2021

Low prevalence of archived M184V/I mutations in 3 HIV-1 suppressed, switch studies

European Meeting on HIV & Hepatitis 2021

Kinetics of archived M184V mutation in HIV-DNA from highly experienced HIV-infected patients with sustained viral suppression

European Meeting on HIV & Hepatitis 2021

HIV-1 reverse transcriptase natural polymorphism V106I does not alter the susceptibility and the genetic barrier to resistance to Doravirine in vitro.

European Meeting on HIV & Hepatitis 2021

Virological efficacy of switch to 3TC/DTG in a real life cohort of suppressed HIV-1 patients with or without past M184V – The LAMRES Study

European Meeting on HIV & Hepatitis 2021

Exploratory Analysis of Baseline Phenotypic and Genotypic Parameters in Relation to Antiviral Activity for Fostemsavir (FTR) in Heavily Treatment-Experienced (HTE) Patients in the Phase 3 BRIGHTE Study

European Meeting on HIV & Hepatitis 2021

Determinants of HIV-1 late presentation in patients followed in Europe

European Meeting on HIV & Hepatitis 2021

Exploration of the possible mechanisms leading to greater mortality in people with limited drug options (LDO)

European Meeting on HIV & Hepatitis 2021

Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG+3TC or ATV/r+3TC dual therapy

European Meeting on HIV & Hepatitis 2021

Usefulness of next-generation sequencing on PBMC samples and HIV-1 DNA quantification in management of treatment optimization in HIV-1 infected virologically suppressed individuals

European Meeting on HIV & Hepatitis 2021

APOBEC editing in HIV DNA proviral vif and pol long-reads issued from virologically-suppressed patients included in the ANRS LAMIDOL trial

European Meeting on HIV & Hepatitis 2021

A Multi-Allelic Molecular-Beacon-Based Real-Time RT-PCR Assay for the Detection of the Coronavirus SARS-CoV-2 from Clinical Samples

European Meeting on HIV & Hepatitis 2021

Use of Fibroquel® (type I polymerized collagen) in patients with hypoxemic inflammatory pneumonia secondary to COVID-19 in Veracruz, Mexico.

European Meeting on HIV & Hepatitis 2021

Longitudinal Evaluation of Sequencing Quality in EQA-Schemes from 2014 to 2020

European Meeting on HIV & Hepatitis 2021

PK-virological algorithm to target risk of resistance among key populations in Togo

European Meeting on HIV & Hepatitis 2021

Association of APOBEC3 activity in HIV-1 DNA with non-B HIV-1 and low HIV-1 reservoir

European Meeting on HIV & Hepatitis 2021

Characterization of the newly proposed HIV-1 lineage within subtype A, sub-subtype A7

European Meeting on HIV & Hepatitis 2021

Molecular epidemiology and HIV-1 variant evolution in Poland between 2015 and 2019

European Meeting on HIV & Hepatitis 2021

Epidemiology and transmission of drug resistance mutations among treatment-naïve people living with HIV-1 in Israel, 2010-2018

European Meeting on HIV & Hepatitis 2021

Assessment of HIV-1 DNA quantification methods in the Italian HIV DNA Network

European Meeting on HIV & Hepatitis 2021